JO3713B1 - أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت - Google Patents
أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميتInfo
- Publication number
- JO3713B1 JO3713B1 JOP/2014/0088A JOP20140088A JO3713B1 JO 3713 B1 JO3713 B1 JO 3713B1 JO P20140088 A JOP20140088 A JO P20140088A JO 3713 B1 JO3713 B1 JO 3713B1
- Authority
- JO
- Jordan
- Prior art keywords
- quinuclidin
- thiazol
- propan
- fluorophenyl
- carbamate
- Prior art date
Links
- YFHRCLAKZBDRHN-MRXNPFEDSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(N=1)=CSC=1C1=CC=C(F)C=C1 YFHRCLAKZBDRHN-MRXNPFEDSA-N 0.000 title abstract 2
- 150000003839 salts Chemical group 0.000 title abstract 2
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 abstract 2
- 108091000114 ceramide glucosyltransferase Proteins 0.000 abstract 2
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
<span dir="RTL">يتعلق الاختراع الحالي بصور جديدة من ملح (</span>S<span dir="RTL">)-كينيوكليدين-3-يل(2-2-(4-فلوروفينيل)ثيازول-4-يل) بروبان-2-يل) كربامات مفيدة كمثبط لإنزيم جلوكوزيل سيراميد سينثاز (</span>GCS<span dir="RTL">) و لعلاج أمراض الأيض، مثل أمراض تخزين الجسيم الحال، سواء بمفرده أو بالترافق مع معالجة بالتعويض عن الإنزيمات، و لعلاج السرطان.</span>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791706P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3713B1 true JO3713B1 (ar) | 2021-01-31 |
Family
ID=50543351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2014/0088A JO3713B1 (ar) | 2013-03-15 | 2014-03-11 | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9518049B2 (ar) |
| EP (1) | EP2970250B1 (ar) |
| JP (1) | JP6438455B2 (ar) |
| KR (1) | KR102302064B1 (ar) |
| CN (1) | CN105189490A (ar) |
| AR (1) | AR095435A1 (ar) |
| AU (1) | AU2014240028B2 (ar) |
| BR (1) | BR112015022907B1 (ar) |
| CA (1) | CA2906691A1 (ar) |
| CL (1) | CL2015002701A1 (ar) |
| DK (1) | DK2970250T3 (ar) |
| EA (1) | EA037527B1 (ar) |
| ES (1) | ES2872326T3 (ar) |
| HR (1) | HRP20210692T1 (ar) |
| HU (1) | HUE054349T2 (ar) |
| IL (1) | IL241229B (ar) |
| JO (1) | JO3713B1 (ar) |
| LT (1) | LT2970250T (ar) |
| MA (1) | MA38488A1 (ar) |
| MX (1) | MX370178B (ar) |
| MY (1) | MY181766A (ar) |
| PH (1) | PH12015502021A1 (ar) |
| PL (1) | PL2970250T3 (ar) |
| PT (1) | PT2970250T (ar) |
| RS (1) | RS61852B1 (ar) |
| SA (1) | SA515361078B1 (ar) |
| SG (1) | SG11201507054YA (ar) |
| SI (1) | SI2970250T1 (ar) |
| TN (1) | TN2015000427A1 (ar) |
| TW (1) | TWI713438B (ar) |
| UY (1) | UY35439A (ar) |
| WO (1) | WO2014152215A1 (ar) |
| ZA (1) | ZA201506602B (ar) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| EP3079695B1 (en) * | 2013-12-11 | 2021-03-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| CN113645969A (zh) * | 2019-02-04 | 2021-11-12 | 建新公司 | 用于治疗与溶酶体贮积症相关的症状和病症的方法 |
| JP2023512366A (ja) | 2020-02-03 | 2023-03-27 | ジェンザイム・コーポレーション | リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法 |
| AU2021311131B2 (en) * | 2020-07-24 | 2026-02-19 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| US20230372313A1 (en) | 2020-07-30 | 2023-11-23 | Genzyme Corporation | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
| WO2022215083A1 (en) * | 2021-04-05 | 2022-10-13 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof |
| JP2025541739A (ja) | 2022-12-01 | 2025-12-23 | ジェンザイム・コーポレーション | Ｃｙｐ３ａ４の強力な又は中程度の阻害剤と組み合わせたベングルスタット |
| WO2025219951A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| WO2025219952A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| WO2025262570A1 (en) | 2024-06-17 | 2025-12-26 | Genzyme Corporation | Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| EP1811991B1 (en) | 2004-11-10 | 2018-11-07 | Genzyme Corporation | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis |
| WO2010091104A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| SI3998078T1 (sl) | 2009-08-28 | 2026-02-27 | Genzyme Corporation | Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze |
| KR101987736B1 (ko) * | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
-
2014
- 2014-03-11 JO JOP/2014/0088A patent/JO3713B1/ar active
- 2014-03-13 AR ARP140100981A patent/AR095435A1/es unknown
- 2014-03-14 CA CA2906691A patent/CA2906691A1/en not_active Abandoned
- 2014-03-14 BR BR112015022907-7A patent/BR112015022907B1/pt active IP Right Grant
- 2014-03-14 JP JP2016502330A patent/JP6438455B2/ja active Active
- 2014-03-14 MX MX2015012295A patent/MX370178B/es active IP Right Grant
- 2014-03-14 EP EP14718854.4A patent/EP2970250B1/en active Active
- 2014-03-14 HR HRP20210692TT patent/HRP20210692T1/hr unknown
- 2014-03-14 TW TW103109465A patent/TWI713438B/zh active
- 2014-03-14 UY UY0001035439A patent/UY35439A/es not_active Application Discontinuation
- 2014-03-14 CN CN201480025303.7A patent/CN105189490A/zh active Pending
- 2014-03-14 US US14/776,432 patent/US9518049B2/en active Active
- 2014-03-14 HU HUE14718854A patent/HUE054349T2/hu unknown
- 2014-03-14 ES ES14718854T patent/ES2872326T3/es active Active
- 2014-03-14 AU AU2014240028A patent/AU2014240028B2/en active Active
- 2014-03-14 MY MYPI2015702973A patent/MY181766A/en unknown
- 2014-03-14 EA EA201591706A patent/EA037527B1/ru unknown
- 2014-03-14 MA MA38488A patent/MA38488A1/fr unknown
- 2014-03-14 SG SG11201507054YA patent/SG11201507054YA/en unknown
- 2014-03-14 DK DK14718854.4T patent/DK2970250T3/da active
- 2014-03-14 KR KR1020157028855A patent/KR102302064B1/ko active Active
- 2014-03-14 PL PL14718854T patent/PL2970250T3/pl unknown
- 2014-03-14 LT LTEP14718854.4T patent/LT2970250T/lt unknown
- 2014-03-14 RS RS20210607A patent/RS61852B1/sr unknown
- 2014-03-14 WO PCT/US2014/027081 patent/WO2014152215A1/en not_active Ceased
- 2014-03-14 SI SI201431813T patent/SI2970250T1/sl unknown
- 2014-03-14 PT PT147188544T patent/PT2970250T/pt unknown
-
2015
- 2015-09-06 IL IL241229A patent/IL241229B/en active IP Right Grant
- 2015-09-07 ZA ZA2015/06602A patent/ZA201506602B/en unknown
- 2015-09-09 PH PH12015502021A patent/PH12015502021A1/en unknown
- 2015-09-13 SA SA515361078A patent/SA515361078B1/ar unknown
- 2015-09-14 CL CL2015002701A patent/CL2015002701A1/es unknown
- 2015-09-15 TN TN2015000427A patent/TN2015000427A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000427A1 (en) | Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate | |
| MX2020002867A (es) | Inhibidores de glucosilceramida sintasa. | |
| MX2019008428A (es) | Inhibidores de glucosilceramida sintasa. | |
| SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| MX2016014306A (es) | Marcadores para terapia con lipoproteinas de alta densidad (hdl). | |
| MX365464B (es) | Prodecimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| TN2013000368A1 (en) | Glucosylceramide synthase inhibitors | |
| TH170238A (th) | รูปเกลือของ (s)-ควินิวคลิดิน-3-อิล (2-(2-(4-ฟลูออโรฟีนิล)ไทอาโซล-4-อิล)โพรเพน-2-อิล)คาร์บาเมต |